Last reviewed · How we verify
Hiprex
At a glance
| Generic name | Hiprex |
|---|---|
| Also known as | Methenanime hippurate |
| Sponsor | University of Texas Southwestern Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Mechanism of Action of Methenamine Hippurate (Hiprex™) in Women With Recurring Urinary Tract Infections. (PHASE4)
- A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection (PHASE2)
- Vitamin C and Hiprex in rUTI (EARLY_PHASE1)
- Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection (PHASE4)
- Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis? (NA)
- The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI (PHASE4)
- Oral Probiotic Supplementation in Pregnancy to Reduce Group B Streptococcus Colonization (PHASE3)
- Urinary Track Infection Prevention After Urogynecological Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hiprex CI brief — competitive landscape report
- Hiprex updates RSS · CI watch RSS
- University of Texas Southwestern Medical Center portfolio CI